HPA 39 is a tungsto-antimoniate compound, closely related to the mineral consensed ion HPA 23, from which it differs only by the presence of a potassium instead of a sodium ion inside the central cage. A single parenteral injection of HPA 39 on the same day as virus inoculation decreased the splenomegaly induced by Friend virus in DBA/2 mice and protected 90% of the infected animals against leukaemia. It also lowered the virus content in spleen extracts compared to untreated animals. The efficiency of treatment with HPA 39 on leukaemic mice at a late stage of the disease suggested that the compound may act at the cellular level as well as by inducing virus growth inhibition. HPA 39 also induced an early decrease of peripheral blood reticulocytes, and of the most differentiated erythroblasts in the bone marrow 1 day after injection of the compound. Mineral condensed ions therefore appear to have multiple biological effects both in vitro and in vivo.
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I N T R O D U C T I O N
The antiviral activity of mineral condensed ions (MCI) has been evidenced by several investigators. To date, HPA 23 (5-tungsto-2-antimoniate) has been the most active MCI in both in vitro and in vivo studies (Jasmin et aL, 1974a, b; Werner et aL, 1976; Tsiang et al., 1978) . HPA 23 has a mol. wt. of 6800 and has a trimeric structure which is characterized by a central cage maintained by a sodium ion. In order to elucidate the relationship between the structure and the mode of action of the MCI, we have extensively investigated the antiviral activity of HPA 39, another MCI with a central cage. HPA 39 also belongs to the group of tungsto-antimoniates (21-tungsto-9-antimoniate). However, it differs from HPA 23 by the presence of a potassium ion instead of a sodium ion in the central cage. We report a number of experiments which demonstrate the anti-leukaemic activity of HPA 39 in Friend leukaemia.
M E T H O D S
HPA 39. HPA 39 was prepared by mixing a tungstate solution with an antimonycontaining solution. The tungstate solution was obtained by mixing 81 g tungsten oxide (WO3) with 40 g solid KOH in 200 ml distilled water. The antimony-containing solution was obtained by dissolving 21.8 g antimony oxide (9b202) in 100 ml 6 M-HC1 and neutralizing with 30 g solid KHCO 3. The antimony solution was then gradually added to the tungstate solution kept at 80 °C. After cooling, a tungsto-antimoniate precipitate was obtained which was recrystallized from distilled water. 
Friend leukaemia virus (FLV).
The polycythaemia-inducing strain of FLV has been routinely passaged in vivo in DBA/2 mice for several years in our laboratory. Virus stocks were prepared from clarified extracts of leukaemic spleens and stored at -8 0 °C. The virus was titrated according to the method described by Rowe & Brodsky (1959) . Titres were expressed as SDs0 (spleen enlarging dose 50%). The treated mice were killed 21 days after virus inoculation. The minimum weight for scoring a leukaemic spleen was 250 mg.
Mice. Twenty to 22 g DBA/2 male mice (Iffa-Credo, Lyon, France and CNRS, Orl6ans, France) were used. Procedure for testing the antiviral activity of HPA 39. A 0.2 ml sample of virus suspension was inoculated intraperitoneally into the mice. HPA 39 solutions were prepared immediately before use by dissolving the recrystaUized product in physiological saline at the appropriate concentration; 0.2 ml was given intraperitoneally. The spleen wt. was determined 21 days after virus inoculation. In one experiment, spleen focus formation was assayed. Serial dilutions of clarified extracts from leukaemic spleens were prepared; six mice were injected with 0.2 ml of viral suspensions at varying concentration and spleen foci were counted 9 days after infection. Helper virus content in the spleen was determied by the S+L -assay (Bassin et al., 1971; Larnicol et aL, 1977) in D 56 murine cells. Student's t-test for small samples was used for the comparison of means and the Wilcoxon test was used to compare survival times.
R E S U L T S

Protective effect of HPA 39 against FL V-induced splenomegaly
Groups of 10 mice were inoculated with 20 SDso FLV and treated, the same day, with a single dose of HPA 39 at concentrations ranging from 50 to 250 mg/kg. After 21 days, the animals were killed, and the mean spleen wt. was determined. Results obtained in repeated experiments (Table 1) indicated that the mean spleen wt. was significantly reduced after administration of 50 to 100 mg/kg HPA 39. The dose of 250 mg/kg was shown to be highly toxic. Some animals treated with this concentration died within 7 days after injection.
The protective effect of 100 mg/kg of HPA 39 on mice inoculated with 5, 10, 20 and 50 SDs0 FLV was then tested. As shown in Table 2 , HPA 39 strongly inhibited the splenomegaly induced by FLV over the range of virus concentrations tested.
Time of action of HPA 39
The results of a representative experiment in which a single injection of 100 mg/kg of HPA 39 was given at various times before or after virus inoculation are reported in Table 3 . HPA 39 had no significant effect on splenomegaly when injected 7 days, 4 days or 2 days before virus inoculation. In contrast, HPA 39 did reduce splenomegaly when injected 2 days after virus inoculation. At a higher concentration (250 mg/kg), HPA 39 was shown to reduce splenomegaly when administered up to 17 days after FLV inoculation. However, this concentration was extremely toxic and therefore was not tested further in subsequent experiments.
Study of antiviral and anti-leukaemic effect of HPA 39
Splenomegaly, survival time and FLV production in the spleen, following early or late treatment with HPA 39, were investigated. Groups of 30 mice were inoculated at day 0 with 20 SDs0 of FLV and either treated with 150 mg/kg of HPA 39 at day 0 or at day +17. Controls (30 mice) were inoculated with virus only. At day +21, 10 animals from each group were sacrificed. After weighing, the spleens were pooled. An extract was prepared and titrated as described in Methods. Some of the pools were simultaneously titrated in vitro as focus- The mean spleen wt. was determined 21 days after virus inoculation. ~: Virus content of spleen (determined 21 days after virus inoculation) is given as number of focus-forming units.
forming units (f.f.u.), and in vivo as SDso and spleen foci, to assess whether the f.f.u./ leukaemogenic ratio was the same in control and treated groups.
Early treatment with HPA 39 reduced both splenomegaly and virus concentration (Table  4) . Survival times (Fig. 1) were not increased by a single dose of 3 mg HPA 39 at day +17, whereas 90 % of the early-treated mice were alive 150 days after virus inoculation. In one experiment dealing with treatment at day + 17, treated and control mice were sacrificed at day 21 and the spleens were removed and weighed. In the control group, the spleens were enlarged and weighed from 900 to 2360 mg. In the treated group, five mice had an enlarged spleen and three mice had smaller spleens (< 500 mg). The virus titre in large and small spleens was determined using the spleen focus assay. Our results (Table 5) showed that HPA treatment reduced the virus titre by <0.5 log~0 in the group of mice with large spleens and by approx. 1 lOglo in the group with small spleens.
At days + 24, + 31 and + 38, 10 control and 10 treated mice were used for mean spleen wt. determination. As shown in Fig. 2 , the HPA 39 injection delayed the spleen growth for 14 days. However, the leukaemic spleen resumed growth between days +31 and +38 and reached the plateau value of the control. * Twenty SDs0 of FLV were injected into all mice at day 0.
• [" For the treated mice, HPA 39 (100 mg/kg) was injected 17 days after virus inoculation. :~ Mice were sacrificed at day 21 when the spleens were removed and weighed. § The titre in acellular spleen extracts was determined by the focus-forming assay (f.f.u.). II n, Number of animals in group with symptoms.
Haematological effect of HPA 39 in normal mice
These results suggested a possible effect of H P A 39 on haematopoietic precursors or, more specifically, on erythropoiesis. It is known that erythropoietic committed precursors (such as erythropoietin responsive cells) are the target cells for FLV (Fredrickson et al., 1975; Tambourin & Wendling, 1975) . Therefore, the course of the disease can be modified either by acting on the virus, or on the erythropoietic cells or haematopoietic precursor stem cells (CFU-S). We therefore investigated the effect of H P A 39 on some haematological parameters. The evolution of blood and bone-marrow erythroid cells in normal D B A / 2 mice was followed over a period of 10 days after a single intraperitoneal injection of 100 mg/kg H P A 39.
Results of a representative experiment are shown in Fig. 3 . We observed an early decrease of blood reticulocytes followed by a prolonged period of increased blood reticulocytosis from day 6 to day 21; no significant modification of the haematocrit was found during this period. As shown in Fig. 4 , the percentage of proerythroblasts in the bone marrow increased at day 1 but progressively dropped down to 50% of the normal value at day 10. Erythroblastic cells peaked at day 3, decreased at days 1 and 6 and then returned to the normal level at days 8 and 10. All bone marrow cells exhibited a normal morphological aspect over the period examined. Our results clearly show that HPA 39 has a marked anti-leukaemic effect. It significantly reduced the mean spleen wt. in treated animals as compared to controls, and the survival curves indicate a probable cure of the disease in a high proportion of mice. When injected at day 0, the action of HPA 39 on Friend leukaemia is as pronounced as that of HPA 23 (Jasmin et aL, 1974a, b) . Furthermore, the titre of leukaemogenic virus in the spleen was reduced tenfold when mice were treated at day 0, and by < fivefold when mice were treated at day +17.
In the Friend virus system, antiviral drug~ are effective when they block the infection of target cells. This is possible at the early stages of the disease. At a later stage, all the haematopoietic cells are infected, and only drugs which suppress the growth of erythropoietic cells are active (Chirigos et aL, 1965; Jasmin et aL, 1968; Seidel & Opitz, 1979 a, b) .
Our data suggest an effect of HPA 39 on erythropoietic cells. As shown in Fig. 2 , a single administration of HPA 39 significantly reduced spleen growth for more than 7 days and this effect was reversible. This reversibility may account for the lack of efficiency of a single injection of HPA 39 at day +4 or +7, contrasting with the efficiency of daily injection over a period of 5 days.
The efficiency of HPA 39 at day 0, and at day +2 after virus inoculation might also be due, at least partially, to the rapid haematological perturbations induced by HPA 39. Our preliminary data show that the haematological effect of HPA 39, as measured by
